TICKERNERD
Menu
OGIOGIHealthcare · Drug Manufacturers - Specialty & Generic

OGI Stock Forecast: Organigram Global, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$0.93
−2.53% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 9 Oct 2026 — in the lower half.

Market cap
$132.4M
Ticker Nerd rank
42/ 100
Median analyst target
—
Analysts covering
5
Revenue$105.8M+49.4% y/y
Operating income$5.3M
Net income$105.5M
Free cash flow−$3.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
−11.0%
YTD
−44.4%
1Y
−51.1%
From 52W high
−55.7%
From 52W low
+7.3%
$0.87
$2.11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OGI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Organigram Global, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 9 Oct 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
83
Size
72
Volatility
64
Growth
59
Value
47
Quality
43
Momentum
31
Issuance
19
Accruals
13

Revisions (83): Analysts have, on balance, been raising their forecasts.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OGI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OGI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.80$1.00$1.20$1.40$1.60$1.80$2.00Jan 26Apr 26Jul 26Oct 26OGI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 July 2023StifelMaintainsBuy$1.25 → $4.00
11 May 2021CIBCUpgradeNeutral—
14 Apr 2021CIBCDowngradeUnderperformer$5.00 → $3.25
10 Mar 2021BMO CapitalDowngradeUnderperform—
9 Jan 2020Raymond JamesDowngradeMarket Perform—
12 Nov 2019BMO CapitalDowngradeMarket Perform—
11 Oct 2019JefferiesUpgradeBuy—
25 Feb 2019JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

OGI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OGI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Organigram Global, Inc. returned −51.1% against +20.4% for the S&P 500, dividends included.

OGI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26OGIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OGI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+565.2%
Analysts raising
1
Analysts cutting
0
Fundamentals

Organigram Global, Inc. (OGI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.2×

Cheaper than 69% of US stocks

Price / sales
0.4×

Cheaper than 83% of US stocks

Price / book
0.4×

Cheaper than 85% of US stocks

EV / EBITDA
13.6×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
49.4%

Higher than 86% of US stocks

Earnings growth (YoY)
49.4%

Higher than 74% of US stocks

Gross margin
39.2%

Higher than 48% of US stocks

Operating margin
5.0%

Higher than 55% of US stocks

Net margin
28.0%

Higher than 87% of US stocks

Returns & dividend
Return on equity
17.6%

Higher than 78% of US stocks

Return on assets
−0.6%

Higher than 41% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Organigram Global, Inc. (OGI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Organigram Global, Inc. has a market value of $132.4M and an enterprise value of $159.4M.

  • Revenue in the twelve months to 30 June 2026: $309.2M. The latest quarter grew 49.4% year on year.

  • Net income over the same four quarters: $86.6M, a 28.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$29.7M.

  • Shares outstanding: 141.0M.

  • Trailing P/E: 2.2×; forward P/E: 39.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Organigram Global, Inc. employs 1,139 people — $271K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

OGI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
OGIOrganigram Global, Inc.$132.4M42
DERMJourney Medical Corp.$135.6M63
CRDLCardiol Therapeutics, Inc.$149.2M—
BGMBGM Group Ltd.$119.9M40
ORGOOrganogenesis Holdings, Inc.$114.5M50
AKBAAkebia Therapeutics, Inc.$176.9M76
ADCTADC Therapeutics SA$197.0M81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Organigram Global, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OGI news & analysis

Organigram Provides Update on Integration of Sanity Group and Unified Global Operating Model

Business Wire · 15 Oct 2026neutral

Organigram provided an update on the accelerated integration of Sanity Group and its unified global operating model, saying the steps complete Sanity Group’s integration and align the company as one enterprise. The excerpt ends before describing the actions in detail.

Why it matters — The update concerns how Organigram is consolidating Sanity Group and organizing its global operations.

Organigram Global Inc. (OGI:CA) Discusses Strategic Priorities, Growth Initiatives, and Insights from Production Facilities Transcript

Seeking Alpha · 1 Oct 2026neutral

Organigram Global Inc. (OGI:CA) held a discussion covering its strategic priorities, growth initiatives, and insights from its production facilities, as detailed in a Seeking Alpha transcript.

Why it matters — OGI watchers would gain direct insight into the company's stated strategic direction and operational outlook from management commentary.

Organigram Global Targets Profitable Growth With Canada Focus and German Expansion

MarketBeat · 30 Sept 2026positive

Organigram Global outlined a strategy focused on protecting its Canadian market position while boosting profitability, expanding internationally through its Sanity Group acquisition, improving manufacturing efficiency, and applying stricter capital-allocation discipline.

Why it matters — OGI watchers would care because the company has laid out a clear strategic direction spanning Canadian market defense, international growth, and operational improvements.

Organigram Global to Premiere The 2026 OG Investor Session Today at 4:00 p.m. ET on X

Business Wire · 30 Sept 2026neutral

Organigram Global will premiere its 2026 OG Investor Session today, September 30, 2026, at 4:00 p.m. ET on its X account, with simulcasts on LinkedIn and YouTube. The session is designed around questions frequently asked by investors, including where the next phase of growth will come from.

Why it matters — The investor session provides OGI watchers with direct insight into the company's anticipated growth strategy and its responses to common investor questions.

Organigram Global to Host 2026 OG Investor Session

Business Wire · 2 Sept 2026neutral

Organigram Global Inc. announced details of its 2026 OG Investor Session. The company noted it has a new leadership team, completed its first full quarter with Sanity Group, and sharpened its strategy, and looks forward to updating stakeholders.

Why it matters — The investor session will provide Organigram stakeholders with updates on the company's new leadership, integration of Sanity Group, and its go-forward strategy.

FAQ

Frequently asked questions about OGI stock

Is OGI stock a buy right now?

Of the 5 analysts covering Organigram Global, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Organigram Global, Inc. 42 out of 100 across roughly 4,600 US stocks as at 9 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OGI?

As at 9 Oct 2026, Organigram Global, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).

What is the OGI stock forecast for 2030?

No analyst covering Organigram Global, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGI are extrapolating price history, which says nothing about the business.

How has OGI stock performed over the past year?

Organigram Global, Inc. returned -51.1% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organigram Global, Inc. do?

Organigram Global Inc. is a Canadian cannabis company focused on the production and sale of cannabis and cannabis-derived products for medical and adult-use markets.

What is the latest news on OGI?

The most recent item we track (Business Wire, 15 Oct 2026): "Organigram Provides Update on Integration of Sanity Group and Unified Global Operating Model". Organigram provided an update on the accelerated integration of Sanity Group and its unified global operating model, saying the steps complete Sanity Group’s integration and align the company as one enterprise. The excerpt ends before describing the actions in detail.

Company

About Organigram Global, Inc.

Organigram Global Inc. is a Canadian cannabis company focused on the production and sale of cannabis and cannabis-derived products for medical and adult-use markets. Its portfolio includes dried flower, pre-rolls, vapes, beverages, gummies, concentrates, and other product formats distributed through retail, wholesale, and online channels. The company markets its products under brands such as SHRED, Edison Cannabis Co., Big Bag O’ Buds, Monjour, Trailblazer, BOXHOT, and DEBUNK, giving it a broad consumer reach across multiple segments of the regulated cannabis industry. Organigram Global also participates in the supply of plant cuttings and dried flowers to other licensed producers, supporting broader industry operations. Headquartered in Toronto, Canada, Organigram Global plays a significant role in Canada’s legal cannabis market through cultivation, manufacturing, and branded product development.

CEO Mr. James H. Yamanaka · 1,139 employees · Canada · https://www.organigram.ca